Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: CPAMarty who wrote (144)	4/9/1999 11:39:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 52153

Thread: Do you suppose with the Genentech termination of their NGF, recombinant nerve growth factor for diabetic peripheral neuropathy, that we might see a little attention turn to the other players...especially ones off the valuation list? Maybe CEPH, or one which I own REGN? Are their other candidates with fairly advanced clinical trials? Of course in addition I also have that cnsi (r Glial Growth Factor), but as you know I bought that a few years too early, sigh.